Your institution may have access to this item. Find your institution then sign in to continue.
Title
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Authors
Ko AH; Dito E; Schillinger B; Venook AP; Xu Z; Bergsland EK; Wong D; Scott J; Hwang J; Tempero MA
Publication
Investigational new drugs, 2008, Vol 26, Issue 5, p463